• 1
    Lucena J, Rico A, Vázquez R, et al. Pulmonary embolism and sudden-unexpected death: prospective study on 2477 forensic autopsies performed at the Institute of Legal Medicine in Seville. J Forensic Leg Med. 2009;16:196201.
  • 2
    Meyer G, Planquette B, Sanchez O. Long-term outcome of pulmonary embolism. Curr Opin Hematol. 2008;15:499503.
  • 3
    Janjua M, Badshah A, Matta F, et al. Treatment of acute pulmonary embolism as outpatients or following early discharge: a systematic review. Thromb Haemost. 2008;100:756761.
  • 4
    Zondag W, Kooiman J, Klok F, et al. Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis [published online ahead of print October 25, 2012]. Eur Respir J. doi: 10.3410/f.717962387.793468524.
  • 5
    Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:23422352.
  • 6
    EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:24992510.
  • 7
    UK House of Commons, Health Committee, Second Report. The Prevention of Venous Thromboembolism in Hospitalised Patients. Published February 23, 2005. Accessed February 2, 2013.
  • 8
    Van den Belt AG, Bossuyt PM, Prins MH, et al; TASMAN Study Group. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis—an economic evaluation. Thromb Haemost. 1998;79:259263.
  • 9
    Rodger M, Bredeson C, Wells PS, et al. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ. 1998;159:931938.
  • 10
    Gould MK, Dembitzer AD, Sanders GD, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med. 1999;130:789799.
  • 11
    Estrada CA, Mansfield CJ, Heudebert GR. Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis. J Gen Intern Med. 2000;15:108115.
  • 12
    O'Brien B, Levine M, Willan A, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med. 1999;159:22982304.
  • 13
    Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med. 2000;160:29262932.
  • 14
    Spyropoulos AC, Hurley JS, Ciesla GN, et al. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest. 2002;122:108114.
  • 15
    Segal JB, Bolger DT, Jenckes MW, et al. Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. Am J Med. 2003;115:298308.
  • 16
    Bäckman K, Carlsson P, Kentson M, et al. Deep venous thrombosis: a new task for primary health care. A randomised economic study of outpatient and inpatient treatment. Scand J Prim Health Care. 2004;22:4449.
  • 17
    Othieno R, Abu Affan M, Okpo E. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev. 2007;3:CD003076.
  • 18
    Guanella R, Ducruet T, Johri M, et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. J Thromb Haemost. 2011;9:23972405.
  • 19
    Aujesky D, Smith KJ, Cornuz J, et al. Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. Chest. 2005;128:16011610.
  • 20
    Ryttberg L, Diamantopoulos A, Forster F, et al. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. Expert Rev Pharmacoecon Outcomes Res. 2011;11:601615.
  • 21
    Duran A, Sengupta N, Diamantopoulos A, et al. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective. Pharmacoeconomics. 2012;30:87101.
  • 22
    McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics. 2009;27:829846.
  • 23
    British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax. 2003;58:470483.
  • 24
    Wicki J, Perrier A, Perneger TV, et al. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost. 2000;84:548552.
  • 25
    Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172:10411046.
  • 26
    Moores L, Aujesky D, Jiménez D, et al. Pulmonary Embolism Severity Index and troponin testing for the selection of low-risk patients with acute symptomatic pulmonary embolism. J Thromb Haemost. 2010;8:517522.
  • 27
    Barra S, Paiva L, Providência R, et al. LR-PED Rule: Low-Risk Pulmonary Embolism Decision Rule—a new decision score for low-risk pulmonary embolism. Thromb Res. 2012;130:327333.
  • 28
    Erkens PM, Gandara E, Wells PS, et al. Does the Pulmonary Embolism Severity Index accurately identify low risk patients eligible for outpatient treatment? Thromb Res. 2012;129:710714.
  • 29
    Venetz C, Jiménez D, Mean M, et al. A comparison of the original and simplified Pulmonary Embolism Severity Index. Thromb Haemost. 2011;106:423428.
  • 30
    Jiménez D, Yusen RD, Otero R, et al. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest. 2007;132:2430.
  • 31
    Moores L, Zamarro C, Gómez V, et al; for the IRYCIS Pulmonary Embolism Study Group. Changes in PESI score predict mortality in intermediate-risk patients with acute pulmonary embolism. Eur Respir J. 2013;41:354359.
  • 32
    Lankeit M, Jiménez D, Kostrubiec M, et al. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation. 2011;124:27162724.
  • 33
    Barra SN, Paiva LV, Providência R, et al. Atrial fibrillation in acute pulmonary embolism: prognostic considerations [published online ahead of print January 24, 2013]. Emerg Med J. doi:10.1136/emermed-2012-202089.
  • 34
    Zondag W, Mos IC, Creemers-Schild D, et al; Hestia Study Investigators. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost. 2011;9:15001507.
  • 35
    Zondag W, den Exter PL, Crobach MJ, et al; for the Hestia Study Investigators. Comparison of two methods for selection of out of hospital treatment in patients with acute pulmonary embolism. Thromb Haemost. 2013;109:4752.
  • 36
    Zondag W, Vingerhoets LM, Durian MF, et al; Hestia Study Investigators. Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function. J Thromb Haemost. 2013;11:686692.
  • 37
    Paiva LV, Providência RC, Barra SN, et al. Cardiovascular risk assessment of pulmonary embolism with the GRACE risk score. Am J Cardiol. 2013;111:425431.
  • 38
    Lankeit M, Kempf T, Dellas C, et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med. 2008;177:10181025.
  • 39
    Stergiopoulos K, Bahrainy S, Strachan P, et al. Right ventricular strain rate predicts clinical outcomes in patients with acute pulmonary embolism. Acute Card Care. 2011;13:181188.
  • 40
    Platz E, Hassanein AH, Shah A, et al. Regional right ventricular strain pattern in patients with acute pulmonary embolism. Echocardiography. 2012;29:464470.
  • 41
    Descotes-Genon V, Chopard R, Morel M, et al. Comparison of right ventricular systolic function in patients with low risk and intermediate-to-high risk pulmonary embolism: a two-dimensional strain imaging study. Echocardiography. 2013;30:301308.
  • 42
    Araoz PA, Gotway MB, Harrington JR, et al. Pulmonary embolism: prognostic CT findings. Radiology. 2007;242:889897.
  • 43
    Qanadli SD, El Hajjam M, Vieillard-Baron A, et al. New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography. AJR Am J Roentgenol. 2001;176:14151420.
  • 44
    Van der Meer RW, Pattynama PM, van Strijen MJ, et al. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology. 2005;235:798803.
  • 45
    Ghuysen A, Ghaye B, Willems V, et al. Computed tomographic pulmonary angiography and prognostic significance in patients with acute pulmonary embolism. Thorax. 2005;60:956961.
  • 46
    Schoepf UJ, Kucher N, Kipfmueller F, et al. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation. 2004;110:32763280.
  • 47
    Rodrigues B, Correia H, Figueiredo A, et al. Clot burden score in the evaluation of right ventricular dysfunction in acute pulmonary embolism: quantifying the cause and clarifying the consequences [article in Portuguese]. Rev Port Cardiol. 2012;31:687695.
  • 48
    Ghanima W, Abdelnoor M, Holmen LO, et al. The association between the proximal extension of the clot and the severity of pulmonary embolism (PE): a proposal for a new radiological score for PE. J Intern Med. 2007;261:7481.
  • 49
    Wu AS, Pezzullo JA, Cronan JJ, et al. CT pulmonary angiography: quantification of pulmonary embolus as a predictor of patient outcome-initial experience. Radiology. 2004;230:831835.
  • 50
    Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: a prospective cohort study in 1626 patients. Haematologica. 2007;92:199205.
  • 51
    Pengo V, Lensing AWA, Prins MH, et al; for the Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350:22572264.
  • 52
    Kearon C, Akl EA, Comerota AJ, et al; Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published correction appears in Chest. 2012;142:16981704]. Chest. 2012;141(2 suppl):e419S–e494S.
  • 53
    Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis. 2008;25:3744.
  • 54
    Heit JA. Predicting the risk of venous thromboembolism recurrence. Am J Hematol. 2012;87:S63S67.
  • 55
    Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121:16301636.
  • 56
    Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10:10191025.
  • 57
    Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 2000;84:805810.
  • 58
    Ruíz-Giménez N, Suárez C, González R, et al; RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:2631.
  • 59
    Becattini C, Agnelli G, Schenone A, et al; for the WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:19591967.
  • 60
    Brighton TA, Eikelboom JW, Mann K, et al; for the ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367:19791987.
  • 61
    Donzé J, Le Gal G, Fine MJ, et al. Prospective validation of the Pulmonary Embolism Severity Index: a clinical prognostic model for pulmonary embolism. Thromb Haemost. 2008;100:943948.
  • 62
    Aujesky D, Perrier A, Roy PM, et al. Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism. J Intern Med. 2007;261:597604.
  • 63
    Jiménez D, Aujesky D, Moores L, et al; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170:13831389.
  • 64
    Chunilal SD, Eikelboom JW, Attia J, et al. Does this patient have pulmonary embolism? JAMA. 290:28492858.
  • 65
    Zwierzina D, Limacher A, Méan M, et al. Prospective comparison of clinical prognostic scores in elderly patients with pulmonary embolism. J Thromb Haemost. 2012. doi: 10.1111/j.1538-7836.2012.04929.x.
  • 66
    Klok FA, Mos IC, Nijkeuter M, et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med. 2008;168:21312136.
  • 67
    Sam A, Sánchez D, Gómez V, et al. The shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolism. Eur Respir J. 2011;37:762766.
  • 68
    Agterof MJ, Schutgens RE, et al. A prognostic model for short term adverse events in normotensive patients with pulmonary embolism. Am J Hematol. 2011;86:646649.
  • 69
    Uresandi F, Otero R, Cayuela A, et al. [-A clinical prediction rule for identifying short-term risk of adverse events in patients with pulmonary thromboembolism]. Arch Bronconeumol. 2007;43:617622.